Hepatocellular carcinoma (HCC) is one of the leading causes of cancer mortality,
accounting for almost 90% of total liver cancer burden. Surgical resection followed by …

Hepatocellular carcinoma (HCC) represents one of the leading causes of cancer death and
has proved to be highly refractory to treatment. Extensive analysis of the disease has …

Knowing the spontaneous outcome of hepatocellular carcinoma (HCC) is important for
designing randomized controlled trials (RCTs) of new therapeutic approaches; however …

Purpose: Brivanib, a selective dual inhibitor of fibroblast growth factor and VEGF signaling,
has demonstrated encouraging antitumor activity in preclinical and phase I studies. We …

In this study, the anticancer effect of icariin, a natural flavonol glycoside, against human
hepatoma SMMC-7721 cells and the underlying mechanisms were investigated. Icariin …

Angiogenesis is a dynamic, hypoxia-stimulated and growth factor-dependent process, and is
currently referred to as the formation of new vessels from pre-existing blood vessels …

Hepatocellular carcinoma (HCC) is the most common malignant hepatobiliary disease; it is
responsible for about 1 million deaths per year. Risk factors include hepatitis B and C …

Background & Aims Vascular endothelial growth factor (VEGF) regulates angiogenesis, yet
therapeutic strategies to disrupt VEGF signaling can interfere with physiologic angiogenesis …

This review summarizes the epidemiological trend, risk factors, prevention strategies such
as vaccination, staging, current novel therapeutics, including the drugs under clinical trials …

Objective Antiangiogenic strategies have been proposed as a promising new approach for
the therapy of portal hypertension and chronic liver disease. Pigment epithelium-derived …